Sandbox g19: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 13: | Line 13: | ||
::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or [[Ceftriaxone]] 4 g/day q12h {{and}} [[Metronidazole]] 30 mg/kg/day q6h | ::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or [[Ceftriaxone]] 4 g/day q12h {{and}} [[Metronidazole]] 30 mg/kg/day q6h | ||
::* Dental infection | ::* '''Dental infection''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Penicillin G]] 24 MU q4h {{and}} [[Metronidazole]] 30 mg/kg/day q6h | ::::* [[Penicillin G]] 24 MU q4h {{and}} [[Metronidazole]] 30 mg/kg/day q6h | ||
::* Penetrating trauma or post-neurosurgy | ::* '''Penetrating trauma or post-neurosurgy''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
* ([[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h) {{and}} [[Vancomycin]] 30–45 mg/kg/day q8–12h | ::::* ([[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h) {{and}} [[Vancomycin]] 30–45 mg/kg/day q8–12h | ||
::* Lung abscess, empyema, or bronchiectasis | ::* '''Lung abscess, empyema, or bronchiectasis''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Penicillin G]] 24 MU q4h {{and}} [[Metronidazole]] 30 mg/kg/day q6h {{and}} [[TMP-SMZ]] 10–20 mg/kg/day q6–12h | ::::* [[Penicillin G]] 24 MU q4h {{and}} [[Metronidazole]] 30 mg/kg/day q6h {{and}} [[TMP-SMZ]] 10–20 mg/kg/day q6–12h | ||
::* Bacterial endocarditis | ::* '''Bacterial endocarditis''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Vancomycin]] 30–45 mg/kg/day q8–12h {{and}} [[Gentamicin]] 5 mg/kg/day IV q8h | ::::* [[Vancomycin]] 30–45 mg/kg/day q8–12h {{and}} [[Gentamicin]] 5 mg/kg/day IV q8h | ||
::* Congenital heart disease | ::* '''Congenital heart disease''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h | ::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h | ||
::* Transplant recipients | ::* '''Transplant recipients''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* ([[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h) {{and}} [[Metronidazole]] 30 mg/kg/day q6h {{and}} [[Voriconazole]] 8 mg/kg/day q12h {{and}} ([[TMP-SMZ]] 10–20 mg/kg/day q6–12h {{or}} [[Sulfadiazine]] 4–6 g/day q6h) | ::::* ([[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h) {{and}} [[Metronidazole]] 30 mg/kg/day q6h {{and}} [[Voriconazole]] 8 mg/kg/day q12h {{and}} ([[TMP-SMZ]] 10–20 mg/kg/day q6–12h {{or}} [[Sulfadiazine]] 4–6 g/day q6h) | ||
::* Patients with HIV/AIDS | ::* '''Patients with HIV/AIDS''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* ([[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h) {{and}} [[Sulfadiazine]] 4–6 g/day q6h {{and}} [[Pyrimethamine]] 25–100 mg/day qd | ::::* ([[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h) {{and}} [[Sulfadiazine]] 4–6 g/day q6h {{and}} [[Pyrimethamine]] 25–100 mg/day qd | ||
::* Staphylococcus aureus coverage | ::* '''Staphylococcus aureus coverage''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Vancomycin]] 30–45 mg/kg/day q8–12h | ::::* [[Vancomycin]] 30–45 mg/kg/day q8–12h | ||
::* Mycobacterium tuberculosis coverage | ::* '''Mycobacterium tuberculosis coverage''' | ||
::::* [[Isoniazid]] 300 mg qd {{and}} [[Rifampin]] 600 mg qd {{and}} [[Pyrazinamide]] 15–30 mg qd {{and}} [[Ethambutol]] 15 mg/kg/day qd | ::::* [[Isoniazid]] 300 mg qd {{and}} [[Rifampin]] 600 mg qd {{and}} [[Pyrazinamide]] 15–30 mg qd {{and}} [[Ethambutol]] 15 mg/kg/day qd | ||
Revision as of 05:08, 5 June 2015
Brain abscess
- Empiric antimicrobial therapy
- Brain abscess in otherwise healthy patients
- Preferred regimen
- Cefotaxime 8–12 g/day IV q4–6h OR Ceftriaxone 4 g/day IV q12h AND Metronidazole 30 mg/kg/day IV q6h
- Alternative regimen
- Meropenem 6 g/day IV q8h
- Brain abscess with comorbidities
- Otitis media, mastoiditis, or sinusitis
- Preferred regimen
- Cefotaxime 8–12 g/day q4–6h {{or Ceftriaxone 4 g/day q12h AND Metronidazole 30 mg/kg/day q6h
- Dental infection
- Preferred regimen
- Penicillin G 24 MU q4h AND Metronidazole 30 mg/kg/day q6h
- Penetrating trauma or post-neurosurgy
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Vancomycin 30–45 mg/kg/day q8–12h
- Lung abscess, empyema, or bronchiectasis
- Preferred regimen
- Penicillin G 24 MU q4h AND Metronidazole 30 mg/kg/day q6h AND TMP-SMZ 10–20 mg/kg/day q6–12h
- Bacterial endocarditis
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h AND Gentamicin 5 mg/kg/day IV q8h
- Congenital heart disease
- Preferred regimen
- Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h
- Transplant recipients
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Metronidazole 30 mg/kg/day q6h AND Voriconazole 8 mg/kg/day q12h AND (TMP-SMZ 10–20 mg/kg/day q6–12h OR Sulfadiazine 4–6 g/day q6h)
- Patients with HIV/AIDS
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Sulfadiazine 4–6 g/day q6h AND Pyrimethamine 25–100 mg/day qd
- Staphylococcus aureus coverage
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h
- Mycobacterium tuberculosis coverage
- Isoniazid 300 mg qd AND Rifampin 600 mg qd AND Pyrazinamide 15–30 mg qd AND Ethambutol 15 mg/kg/day qd